Welcome to our dedicated page for Boston Scien Cp news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scien Cp stock.
About Boston Scientific Corporation (BSX)
Boston Scientific Corporation (NYSE: BSX) is a global leader in the development, manufacturing, and commercialization of innovative medical technologies designed to improve patient outcomes and reduce healthcare costs. With a legacy spanning over 45 years, the company operates at the forefront of medical advancements, transforming lives through its diverse portfolio of high-performance solutions. Boston Scientific is headquartered in Marlborough, Massachusetts, and serves healthcare professionals and institutions across more than 100 countries.
Core Business Segments
Boston Scientific operates through two primary business segments:
- MedSurg: This segment focuses on minimally invasive technologies for gastrointestinal, urological, and respiratory health. Key product categories include endoscopy devices, stone management solutions, and therapies for chronic pain and incontinence.
- Cardiovascular: This segment encompasses a wide array of devices for interventional cardiology and peripheral interventions. Products include drug-eluting stents, balloon catheters, and advanced therapies for structural heart conditions, cardiac rhythm management, and electrophysiology.
Innovative Product Portfolio
Boston Scientific's portfolio addresses critical needs in multiple therapeutic areas:
- Cardiovascular Health: Devices for angioplasty, cardiac rhythm management, and structural heart interventions, including the WATCHMAN™ Left Atrial Appendage Closure Device and the FARAPULSE™ Pulsed Field Ablation System.
- Oncology: Minimally invasive solutions for interventional oncology and tumor management, including hepatic artery infusion pumps for liver cancer treatment.
- Neurology: Neuromodulation therapies for chronic pain and movement disorders.
- Urology and Pelvic Health: Solutions for kidney stone management, incontinence, and pelvic floor disorders.
Global Reach and Market Presence
Boston Scientific generates nearly half of its revenue from international markets, reflecting its strong global footprint. The company’s strategic acquisitions, such as Silk Road Medical and Bolt Medical, have expanded its capabilities and market share in high-growth areas like vascular medicine and intravascular lithotripsy. Additionally, its focus on emerging markets and innovative product launches positions it as a key player in the medical device industry.
Commitment to Innovation
Research and development are at the core of Boston Scientific's strategy. The company invests heavily in clinical trials and product innovation, as evidenced by its pipeline of next-generation technologies, including the ACURATE neo2™ Aortic Valve System and advanced cardiac mapping solutions. Boston Scientific's commitment to advancing science for life is further demonstrated by its leadership in clinical studies, such as the OPTION and ADVANTAGE AF trials, which provide robust evidence for its devices’ safety and efficacy.
Competitive Landscape
Boston Scientific operates in a highly competitive market alongside peers like Medtronic and Abbott Laboratories. The company differentiates itself through its diversified product offerings, focus on minimally invasive solutions, and category leadership strategy. Its ability to integrate acquisitions and deliver consistent financial performance underscores its resilience and adaptability in a dynamic healthcare environment.
Market Challenges and Opportunities
While Boston Scientific faces challenges such as regulatory complexities, pricing pressures, and supply chain dynamics, it is well-positioned to capitalize on opportunities in high-growth areas like atrial fibrillation treatment, structural heart interventions, and interventional oncology. The company’s focus on addressing unmet medical needs and enhancing procedural efficiency ensures its continued relevance and growth potential.
Conclusion
Boston Scientific Corporation exemplifies innovation and excellence in the medical technology industry. By delivering cutting-edge solutions that improve patient outcomes and reduce healthcare costs, the company continues to transform lives globally. Its strategic focus on category leadership, robust R&D pipeline, and commitment to addressing unmet clinical needs make it a cornerstone of modern healthcare.
Boston Scientific (NYSE: BSX) has announced an agreement to acquire SoniVie , developer of the investigational TIVUS™ Intravascular Ultrasound System for treating hypertension through renal denervation (RDN). The acquisition expands BSX's Interventional Cardiology Therapies portfolio.
The transaction includes an upfront payment of approximately $360 million for the 90% stake not currently owned by BSX (which holds ~10% equity), plus up to $180 million in regulatory milestone payments. The TIVUS system uses ultrasound energy to denervate renal arteries, potentially offering deeper tissue penetration and faster procedures compared to radiofrequency alternatives.
The deal is expected to close in first half 2025, with slight dilution to adjusted EPS in 2025, which BSX plans to offset through internal cost efficiencies. SoniVie recently reported positive efficacy data from an IDE pilot trial and has initiated the THRIVE global IDE pivotal trial.
Boston Scientific (NYSE: BSX) announced that its wholly owned finance subsidiary, American Medical Systems Europe B.V., has completed a public offering of €1.5 billion in senior notes. The offering consists of €850 million in 3.000% notes due 2031 and €650 million in 3.250% notes due 2034.
The notes, fully guaranteed by Boston Scientific, will be listed on the Euronext Dublin Global Exchange Market. The proceeds will be used to repay AMS Europe's 0.750% senior notes maturing March 8, 2025, pay accrued interest, and support general corporate purposes, including short-term investments, debt reduction, working capital, and potential acquisitions.
Boston Scientific (NYSE: BSX) announced that its wholly owned finance subsidiary, American Medical Systems Europe B.V., has priced a public offering of €1.5 billion in senior notes. The offering consists of €850 million in 3.000% notes due 2031 and €650 million in 3.250% notes due 2034.
The notes, fully guaranteed by Boston Scientific, are expected to close on February 26, 2025. The company plans to use the proceeds, along with cash on hand, to repay AMS Europe's 0.750% senior notes maturing March 8, 2025, pay accrued interest, and support general corporate purposes including short-term investments, debt reduction, working capital, and potential future acquisitions.
Boston Scientific (NYSE: BSX) has announced its participation in TD Cowen's 45th Annual Health Care Conference scheduled for March 4, 2025. The company will be represented by three key executives: Dan Brennan (Executive VP and CFO), Art Butcher (Executive VP and Group President, MedSurg and Asia Pacific), and Dr. Kenneth Stein (Senior VP and Chief Medical Officer).
The executives will engage in a 30-minute fireside chat with the host analyst, beginning at approximately 9:10 a.m. ET. The session will be available via live webcast, with a replay accessible on the company's investor relations website approximately one hour after the event concludes.
Boston Scientific (BSX) reported strong financial results for Q4 and full year 2024. Q4 net sales reached $4.561 billion, growing 22.4% on a reported basis, with GAAP EPS of $0.38 and adjusted EPS of $0.70. Full-year 2024 net sales were $16.747 billion, up 17.6%, with GAAP EPS of $1.25 and adjusted EPS of $2.51.
The company showed significant growth across segments, with Cardiovascular growing 28.8% and MedSurg up 12.4% in Q4. Regional performance was led by the U.S. with 30.7% growth. Notable developments include positive clinical trial results for WATCHMAN FLX™ and FARAPULSE™ systems, plus strategic acquisitions of Axonics and Cortex.
For 2025, BSX projects full-year net sales growth of 12.5-14.5% on a reported basis and adjusted EPS of $2.80-$2.87. Q1 2025 guidance indicates 17-19% reported sales growth with adjusted EPS of $0.66-$0.68.
Boston Scientific (BSX) announced positive clinical data for two key atrial fibrillation therapies at AF Symposium 2025. The ADVANTAGE AF trial for the FARAPULSE™ PFA System met its primary endpoints, showing a 2.3% safety event rate and 63.5% effectiveness rate in treating persistent AF patients, with an 85.3% symptomatic AF recurrence-free rate.
A sub-analysis of the OPTION trial demonstrated that the WATCHMAN FLX™ device significantly reduced bleeding outcomes compared to oral anticoagulants. Concomitant procedures showed a 44% reduction (8.0% vs. 13.3%) while sequential procedures demonstrated a 62% reduction (8.8% vs. 21.5%) in non-procedural bleeding at 36 months. Both approaches maintained similar efficacy outcomes and stroke protection compared to oral anticoagulants.
Boston Scientific (NYSE: BSX) has announced a definitive agreement to acquire Bolt Medical, developer of an intravascular lithotripsy (IVL) advanced laser-based platform for treating coronary and peripheral artery disease. The acquisition includes an upfront payment of $443 million for the 74% stake not yet owned, plus potential regulatory milestone payments of up to $221 million.
Boston Scientific, which already holds a 26% equity stake in Bolt Medical since helping establish it in 2019, aims to expand its cardiovascular portfolio with this complementary calcium modification platform. The Bolt IVL™ system uses novel lithotripsy technology to fracture calcium through acoustic pressure waves inside a balloon catheter.
Bolt Medical recently completed the RESTORE ATK and BTK pivotal clinical trials and received FDA approval to commence the global FRACTURE IDE clinical trial for coronary arterial disease treatment. The transaction is expected to close in first half 2025 and be slightly dilutive to adjusted EPS in 2025.
Sherpa Healthcare Partners has appointed Raymond W. Cohen as Venture Partner. Cohen, a veteran healthcare executive, recently served as CEO and board member of Axonics, a medical technology company he co-founded in 2013 and took public in 2018. Under his leadership, Axonics achieved notable recognition, ranking first in both the 2021 Deloitte Technology Fast 500™ and 2022 Financial Times fastest-growing companies in the Americas list.
Cohen retired as CEO following Boston Scientific 's (NYSE: BSX) $3.7 billion acquisition of Axonics in November 2024. Before Axonics, he was CEO of Vessix Vascular, which was also acquired by Boston Scientific in 2012. The appointment aims to leverage Cohen's extensive experience in growing MedTech companies to support Sherpa's investment activities in innovative healthcare technologies.
Boston Scientific (NYSE: BSX) has announced two upcoming investor events. First, the company will participate in the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, in San Francisco. CEO Mike Mahoney will present at 5:15 p.m. PT, joined by CFO Dan Brennan and CMO Dr. Kenneth Stein for a Q&A session.
Additionally, BSX will host its fourth quarter 2024 earnings call on February 5, 2025, at 8:00 a.m. ET. Financial results will be released prior to the call. Both events will be accessible via webcast on the company's investor relations website, with replays available approximately one hour after each event.
Boston Scientific (NYSE: BSX) has announced a definitive agreement to acquire Intera Oncology Inc., gaining access to the Intera 3000 Hepatic Artery Infusion Pump and floxuridine chemotherapy drug. The acquisition targets liver cancer treatment, particularly for metastatic colorectal cancer patients. The Intera 3000 pump, the only FDA-approved constant flow implantable pump for HAI therapy in the US, delivers continuous chemotherapy directly to the liver. Clinical trials have shown significant improvements in tumor response, progression time, and survival rates compared to systemic chemotherapy. The transaction is expected to close in first half 2025, with immaterial impact on adjusted EPS but more dilutive on GAAP basis.
FAQ
What is the current stock price of Boston Scien Cp (BSX)?
What is the market cap of Boston Scien Cp (BSX)?
What does Boston Scientific Corporation specialize in?
What are Boston Scientific's core business segments?
How does Boston Scientific differentiate itself from competitors?
What are some of Boston Scientific's key products?
What is Boston Scientific's global market presence?
How does Boston Scientific invest in innovation?
What challenges does Boston Scientific face in its industry?
What are Boston Scientific's growth areas?
What is Boston Scientific's commitment to healthcare innovation?
Who are Boston Scientific's main competitors?
